S
Signadori Bio
The next-generation cellular immunotherapy for cancer cure
About Signadori Bio
Signadori Bio is a preclinical-stage biopharmaceutical company that emerged in 2025 as a strategic collaboration between the European life sciences venture capital firm Sofinnova Partners and Gustave Roussy, a premier cancer center in Europe. The company was established with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, leveraging their research conducted at Gustave Roussy. The venture is steered by CEO Matthieu Coutet, who is also a Partner at Sofinnova Partners.
The firm is focused on developing a next-generation cell therapy platform to address the complexities of treating solid tumors. Signadori Bio's core technology centers on a monocyte-based cell therapy approach. This involves harnessing the immune potential of gene-modified monocytes and macrophages to overcome the challenging tumor microenvironment. The company's business model is centered on advancing its proprietary platform from the preclinical stage through to clinical trials and eventual commercialization. As a venture capital-backed entity, its operations are financed through strategic investments. In March 2025, it was announced as one of the first companies to receive investment from Sofinnova's €165 million Biovelocita II fund, which is supported by major pharmaceutical players like Amgen and Bristol Myers Squibb. Invivo Partners also joined as an investor, further strengthening the company's financial and strategic foundation.
Headquartered in Paris, France, Signadori Bio is currently in the preclinical stage of development. A significant milestone was the establishment of a partnership with eXmoor Pharma in June 2025 to accelerate the development and manufacturing of its lead candidate. This collaboration is designed to guide the therapy program through critical development milestones, with a long-term goal of GMP-compliant manufacturing for first-in-human clinical trials. The company aims to make more information public as it moves out of stealth mode.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 45.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Oncology, Immunotherapy, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2026 | $12M | $49M | Sofinnova Partners · Invivo Partners · Taiho Ventures | ↗ |
| EARLY VC✓Equity / VC | Apr 2025 | $0 | — | Invivo Partners | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Signadori Bio in the Paris ecosystem
The Signadori Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Sofinnova Partners- TVTaiho Ventures
Series A1 investor entered at this stage
Invivo Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Signadori Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Signadori Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









